MedPath

Response To Medical Therapy in Inflammatory Bowel Disease Patients Carrying-out a Prescribed Exercise Programme

Not Applicable
Conditions
Inflammatory Bowel Diseases
Interventions
Behavioral: Physician-prescribed Exercise Programme
Drug: Best Medical Therapy
Registration Number
NCT05174754
Lead Sponsor
Royal College of Surgeons, Ireland
Brief Summary

The investigators propose the use of a 20 week physician-derived exercise programme will lead to an improvement in physical fitness which will in turn lead to an increase in muscle mass, a reduction in visceral obesity resulting in an improvement in biologic response, disease biomarkers (including a reduction in circulating pro-inflammatory cytokines), fatigue scores and quality of life.

Detailed Description

After completion, the investigators expect to describe the significant impact that exercise has on IBD disease control, response to biologics, modification of pro-inflammatory cytokine levels, quality of life and fatigue scores.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
70
Inclusion Criteria
  • 18 years of age or above.
  • Confirmed moderate to severe inflammatory bowel disease based on endoscopic evaluation, clinical scoring tools and faecal calprotectin.
  • Be able to provide written informed consent.
  • Stable dose of steroids.
  • Physically able to complete an exercise programme.
  • Healthy controls.
Exclusion Criteria
  • Inability to participate in the exercise program (unable to perform 6MWT, unable to attend for assessment of parameters at any time point).
  • An uncontrolled cardiovascular condition such as unstable angina, uncontrolled cardiac arrhythmias, uncontrolled symptomatic heart failure or symptomatic severe aortic stenosis.
  • A significant musculoskeletal condition, neurological condition, mental illness or intellectual disability that restricts participation in a physical exercise program.
  • Pregnancy.
  • Healthy controls with underlying inflammatory conditions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Inflammatory Bowel Disease Exercise GroupBest Medical TherapyThe exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
Inflammatory Bowel Disease Exercise GroupPhysician-prescribed Exercise ProgrammeThe exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
Inflammatory Bowel Disease Control GroupBest Medical TherapyThe IBD control group will be randomized to best medical therapy alone.
Primary Outcome Measures
NameTimeMethod
The recruitment rates in both IBD arms.26 weeks

A calculation of the percentage of people approached who participate in the intervention (recruitment).

The retention rate in both IBD arms.26 weeks

A calculation of the percentage of people approached who complete the intervention.

The adherence rate in both IBD arms.26 weeks

A calculation of the percentage of people approached who adhered to the intervention.

Secondary Outcome Measures
NameTimeMethod
Change in muscle mass measured by bioelectrical impedance analysis26 weeks

Bioelectrical impedance analysis (muscle mass in Kg)

Change in muscle mass measured by ultrasound26 weeks

Ultrasound of thigh muscle mass (vastus intermedius and rectus femoris-measured in mm, subcutaneous adiposity measured in mm)

Change in visceral fat measured by bioelectrical impedance analysis26 weeks

Bioelectrical impedance analysis (visceral fat in Kg)

Change in fatigue score between the IBD groups in response to exercise12 and 26 weeks

Measured using the Fatigue Severity Scale which comprises nine statements, describing the severity and impact of fatigue, with a scale of possible responses ranging from 1 ("strongly disagree") to 7 ("strongly agree").

Inflammatory response between IBD groups measured using C-Reactive protein12 and 26 weeks

Change in C-Reactive Protein (mg/L)

Inflammatory response between IBD groups measured using pro-inflammatory cytokines12 and 26 weeks

Change in circulating pro-inflammatory cytokines (pg/mL)

Clinical remission in response to exercise intervention12 and 26 weeks

Harvey Bradshaw Index 2 or lower in Crohn's disease patients or partial Mayo score 0-1in ulcerative colitis

Change in Quality of Life in response to exercise12 and 26 weeks

Measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)- a ten item questionnaire, with 1 to 7 points for each item and higher scores indicating higher quality of life.

Change in handgrip strength12 and 26 weeks

Use of Jamar dynamometer to measure handgrip strength in kPa

Change in endoscopic disease activity between IBD groups26 weeks

A change in endoscopic appearance of Crohn's using Simple endoscopic score for Crohn's disease (SES CD) (inactive when SES-CD was 0-2; mild when 3-6; moderate 7-15; and severe \>16) or Mayo score for ulcerative colitis (Score 0-3, Mayo 3 indicating severe disease, 2 moderate disease, 1 mild disease and 0 inactive).

Inflammatory response between IBD groups measured using faecal calprotectin12 and 26 weeks

Change in faecal calprotectin (ug/g)

A change in physical fitness between the IBD patient arms26 weeks

15% difference in 6-minute walk test (6MWT) distance between the two groups

Trial Locations

Locations (1)

Beaumont Hospital

🇮🇪

Dublin, Ireland

© Copyright 2025. All Rights Reserved by MedPath